Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
‘Handmaid’s Tale’ exec reveals when spinoff ‘The Testaments’ will begin filming — and it’s sooner than you think
The Post caught up with several stars and crew members of “The Handmaid’s Tale” at the show’s sixth and final season premiere ...
STAT4d
Rollout of ‘miracle’ HIV prevention drug is threatened by Trump cuts to global AIDS relief program
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
'The Handmaid's Tale' to continue in new series with Ann Dowd and more
Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...
Zacks Investment Research on MSN3d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
Making Progress for People Affected by Liver Disease
The liver is one of the body’s most vital organs, working tirelessly behind the scenes to detoxify, regulate metabolism, ...
Major HIV drug maker to cut nearly 150 Bay Area jobs
On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...
Zacks Investment Research on MSN2d
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...